Ana Corteguera, DO
Family Medicine · Sugar Land, TXNPI 1699700765
Payments from drug & device makers
Across 488 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Abbott$813
- GSK$669
- Lilly USA, LLC$567
- Pfizer$538
- plus $3K from 33 others
What the payments were for
- Food & beverage$9,078100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 103 | $2,054 |
| AbbVie(2 entities) | 61 | $1,011 |
| Abbott | 41 | $813 |
| GSK | 46 | $669 |
| Lilly USA, LLC | 24 | $567 |
| Pfizer | 31 | $538 |
| Sanofi-aventis U.S. LLC | 23 | $428 |
| AstraZeneca | 21 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $246 |
| Merck | 15 | $243 |
| IBSA Pharma Inc. | 14 | $237 |
| Eisai Inc. | 10 | $205 |
| Astellas Pharma US Inc | 10 | $201 |
| Amgen | 11 | $201 |
| Shield Therapeutics Inc | 9 | $192 |
| Exact Sciences | 10 | $175 |
| Dexcom, Inc. | 7 | $139 |
| Boehringer Ingelheim | 6 | $114 |
| Currax Pharmaceuticals LLC | 6 | $96 |
| Medtronic | 1 | $62 |
| Renalytix AI, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Hologic Sales And Service, LLC | 2 | $41 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Bayer | 1 | $27 |
| Organon | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Alvogen Inc | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Corium, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$264
- Wegovy$122
- MOUNJARO$115
How this compares
$9,095 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $123,364 |
| MounjaroTirzepatide | 47 | $57,971 |
| JardianceEmpagliflozin | 44 | $54,117 |
| TrulicityDulaglutide | 26 | $27,860 |
| JanuviaSitagliptin Phosphate | 17 | $26,522 |
| FarxigaDapagliflozin Propanediol | 22 | $25,014 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $14,739 |
| MyrbetriqMirabegron | 21 | $13,377 |
| RybelsusSemaglutide | 14 | $11,663 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,900 |
| SynthroidLevothyroxine Sodium | 93 | $5,988 |
| PremarinEstrogens, Conjugated | 13 | $5,422 |
| DiovanValsartan | 13 | $5,000 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,996 |
| Levothyroxine Sodium | 408 | $3,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,054 | $135,027118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $567 | $85,83273 claims |
| Boehringer IngelheimJardiance | $114 | $54,11744 claims |
| MerckJanuvia | $243 | $26,52217 claims |
| AstraZenecaFarxiga | $420 | $25,01422 claims |
| Astellas Pharma US IncMyrbetriq | $201 | $13,37721 claims |
| AbbVieSynthroid | $1,011 | $5,98893 claims |
| PfizerPremarin | $538 | $5,42213 claims |
| Sanofi-aventis U.S. LLCLantus | $428 | $1,30813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Wilner JeudySugar Land$6M
- Ronald PucilloSugar Land$5.1M
- Mehjabin ParkarSugar Land$3.9M
- John VanderzylSugar Land$3.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.